<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02016924</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-216-0128</org_study_id>
    <secondary_id>2013-001402-28</secondary_id>
    <nct_id>NCT02016924</nct_id>
  </id_info>
  <brief_title>Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants</brief_title>
  <official_title>A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cohort 1:

      The primary objectives are:

        -  To evaluate the steady-state pharmacokinetics (PK) of Atazanavir (ATV) and Darunavir
           (DRV) and confirm the dose of Cobicistat-boosted Atazanavir (ATV/co) or
           Cobicistat-boosted Darunavir (DRV/co) in HIV-1 infected, virologically suppressed
           adolescent participants weighing ≥ 25 kg (12 to &lt; 18 years of age)

        -  To evaluate the safety and tolerability of ATV/co or DRV/co through 24 weeks in HIV-1
           infected, virologically suppressed adolescent participants weighing ≥ 25 kg (12 to &lt; 18
           years of age)

      Cohort 2:

      The primary objectives are:

        -  To evaluate the steady-state PK of ATV and DRV and confirm the dose of ATV/co or DRV/co
           in HIV-1 infected, virologically suppressed pediatric participants weighing ≥ 25 to &lt; 35
           kg (6 to &lt; 12 years of age)

        -  To evaluate the steady-state PK of tenofovir alafenamide (TAF) and confirm the dose of
           emtricitabine/tenofovir alafenamide (F/TAF) in HIV-1 infected, virologically suppressed
           pediatric participants weighing ≥ 25 to &lt; 35 kg (6 to &lt; 12 years of age)

        -  To evaluate the safety and tolerability of ATV/co, DRV/co, and F/TAF through 24 weeks in
           HIV-1 infected, virologically suppressed pediatric participants weighing ≥ 25 to &lt; 35 kg
           (6 to &lt; 12 years of age)

      Cohort 3:

      The primary objectives are:

        -  To evaluate the steady-state PK of ATV and DRV and confirm the dose of ATV/co or DRV/co
           in HIV-1 infected, virologically suppressed pediatric participants weighing ≥ 14 to &lt; 25
           kg (≥ 3 years of age)

        -  To evaluate the steady-state PK of TAF and confirm the dose of F/TAF in HIV-1 infected,
           virologically suppressed pediatric participants weighing ≥ 14 to &lt; 25 kg (≥ 3 years of
           age)

        -  To evaluate the safety and tolerability of ATV/co, DRV/co, and F/TAF through 24 weeks in
           HIV-1 infected, virologically suppressed pediatric participants weighing ≥ 14 to &lt; 25 kg
           (≥ 3 years of age)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      13April2020: The study recruitment is currently on pause due to the coronavirus disease
      (COVID-19) pandemic. The overall status will be updated when the study begins recruiting
      again
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 16, 2014</start_date>
  <completion_date type="Anticipated">April 2026</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: AUCtau of ATV and DRV</measure>
    <time_frame>Predose, 1, 2, 3, 4, 5, 8, and 12 hours postdose on Day 10</time_frame>
    <description>AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: AUCtau of ATV, DRV, and TAF for Cohorts 2 and 3</measure>
    <time_frame>Predose 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Week 2 or Week 4</time_frame>
    <description>AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Treatment Emergent Adverse Events (AEs) and Treatment Emergent Laboratory Abnormalities Through Week 24</measure>
    <time_frame>First dose date and up to 24 weeks plus 30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Ctau of ATV, DRV, and COBI for Cohort 1</measure>
    <time_frame>Intensive PK samples at Predose, 1, 2, 3, 4, 5, 8, and 12 hours postdose on Day 10. Trough PK samples at Day 1 prior to adminstering COBI and at Weeks 12, 24, and 48 (Part A), or at Weeks 4, 12, 24, 32, and 48 (Part B).</time_frame>
    <description>Ctau is defined as the observed drug concentration at the end of the dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Cmax of ATV, DRV, and COBI for Cohort 1</measure>
    <time_frame>Intensive PK samples at Predose, 1, 2, 3, 4, 5, 8, and 12 hours postdose on Day 10. Trough PK samples at Day 1 prior to adminstering COBI and at Weeks 12, 24, and 48 (Part A), or at Weeks 4, 12, 24, 32, and 48 (Part B).</time_frame>
    <description>Cmax is defined as the maximum observed concentration of drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: CL/F of ATV, DRV, and COBI for Cohort 1</measure>
    <time_frame>Intensive PK samples at Predose, 1, 2, 3, 4, 5, 8, and 12 hours postdose on Day 10. Trough PK samples at Day 1 prior to adminstering COBI and at Weeks 12, 24, and 48 (Part A), or at Weeks 4, 12, 24, 32, and 48 (Part B).</time_frame>
    <description>CL/F is defined as the apparent oral clearance following administration of the drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Vz/F of COBI for Cohort 1</measure>
    <time_frame>Intensive PK samples at Predose, 1, 2, 3, 4, 5, 8, and 12 hours postdose on Day 10. Trough PK samples at Day 1 prior to adminstering COBI and at Weeks 12, 24, and 48 (Part A), or at Weeks 4, 12, 24, 32, and 48 (Part B).</time_frame>
    <description>Vz/F is defined as the apparent volume of distribution of the drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Ctau of ATV, DRV, COBI, FTC, and TFV for Cohorts 2 and 3</measure>
    <time_frame>Intensive PK samples at Predose 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Week 2 or Week 4. Trough PK samples at Weeks 8, 24, and 36, and timed PK samples (15 minutes to 3 hours post-dose) at Weeks 12, 16, and 48</time_frame>
    <description>Ctau is defined as the observed drug concentration at the end of the dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Cmax of ATV, DRV, COBI, TAF, FTC and TFV for Cohorts 2 and 3</measure>
    <time_frame>Intensive PK samples at Predose 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Week 2 or Week 4. Trough PK samples at Weeks 8, 24, and 36, and timed PK samples (15 minutes to 3 hours post-dose) at Weeks 12, 16, and 48</time_frame>
    <description>Cmax is defined as the maximum observed concentration of drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: CL/F of ATV, DRV, and TAF for Cohorts 2 and 3</measure>
    <time_frame>Intensive PK samples at Predose 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Week 2 or Week 4. Trough PK samples at Weeks 8, 24, and 36, and timed PK samples (15 minutes to 3 hours post-dose) at Weeks 12, 16, and 48</time_frame>
    <description>CL/F is defined as the apparent oral clearance following administration of the drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Vz/F of COBI and TAF for Cohorts 2 and 3</measure>
    <time_frame>Intensive PK samples at Predose 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Week 2 or Week 4. Trough PK samples at Weeks 8, 24, and 36, and timed PK samples (15 minutes to 3 hours post-dose) at Weeks 12, 16, and 48</time_frame>
    <description>Vz/F is defined as the apparent volume of distribution of the drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of treatment-emergent AEs and treatment-emergent laboratory abnormalities through Week 48</measure>
    <time_frame>Up to 48 weeks plus 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants with HIV-1 RNA &lt; 50 copies/mL at Week 24 and as defined by the US FDA-defined snapshot algorithm</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in CD4+ cell counts</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in CD4+ cell counts</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in CD4+ percentages</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in CD4+ percentages</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability of COBI and F/TAF as Measured by Palatability</measure>
    <time_frame>Day 1, and at Weeks 4 (Day 10 for Cohort 1 Part A), 24 and 48.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Acquired Immune Deficiency Syndrome (AIDS)</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Part A, Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants ages 12 to &lt;18 years old will receive cobicistat 150 mg with either ATV or DRV plus BR. The BR may contain additional antiretroviral agents except for the following disallowed agents: saquinavir, indinavir, nelfinavir, double protease inhibitor (PI) regimens, raltegravir, elvitegravir, efavirenz, nevirapine, delavirdine, maraviroc, etravirine, rilpivirine, dolutegravir, and investigational antiretroviral agents.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants ages 6 to &lt;12 years old will receive cobicistat 150 mg and emtricitabine/tenofovir alafenamide 200/25 mg with either ATV or DRV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants ages ≥ 3 will receive cobicistat 90 mg and F/TAF 120/15 mg with either ATV or DRV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants ages 12 to &lt;18 years old will receive cobicistat 150 mg with either ATV or DRV plus BR. The BR may contain additional antiretroviral agents except for the following disallowed agents: saquinavir, indinavir, nelfinavir, double protease inhibitor (PI) regimens, raltegravir, elvitegravir, efavirenz, nevirapine, delavirdine, maraviroc, etravirine, rilpivirine, dolutegravir, and investigational antiretroviral agents.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATV</intervention_name>
    <description>Capsules administered once daily according to dosing recommendations per product monograph</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Part A, Cohort 1</arm_group_label>
    <arm_group_label>Part B, Cohort 1</arm_group_label>
    <other_name>Reyataz®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DRV</intervention_name>
    <description>Tablets administered once daily according to dosing recommendations per product monograph</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Part A, Cohort 1</arm_group_label>
    <arm_group_label>Part B, Cohort 1</arm_group_label>
    <other_name>Prezista®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobicistat</intervention_name>
    <description>Tablets administered orally once daily with food</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Part A, Cohort 1</arm_group_label>
    <arm_group_label>Part B, Cohort 1</arm_group_label>
    <other_name>GS-9350</other_name>
    <other_name>Tybost®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BR</intervention_name>
    <description>Prior to implementation protocol amendment 7, Background Regimen (BR) must include 2 nucleoside reverse transcriptase inhibitors (NRTI). After implementation of protocol amendment 7, BR must include 2 NRTIs and a third agent per local prescribing guidelines.</description>
    <arm_group_label>Part A, Cohort 1</arm_group_label>
    <arm_group_label>Part B, Cohort 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  HIV-1 infected treatment-experienced, virologically suppressed males and females aged
             3 years to &lt; 18 years at the Day 1 visit (according to requirements of enrolling
             Cohort)

          -  Body weight at screening ≥ 25 kg (Cohorts 1), 14 kg to &lt; 25 kg (Cohort 3)

          -  Stable antiretroviral regimen including 2 nucleoside reverse transcriptase inhibitors
             and either ritonavir-boosted atazanavir or ritonavir-boosted darunavir once or twice
             daily as per product label for a minimum of 3 months prior to the screening visit.
             Treatment-experienced pediatric individuals taking DRV/r must have no history of DRV
             resistance associated mutations.

          -  Documented negative screening for active pulmonary tuberculosis (TB) per local
             standard of care within 6 months of a screening visit

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pediatric Infectious Disease Associates</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The George Washington University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Agudos Cosme Argerich</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1151</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Huesped</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1202</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Pediatría Garrahan</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1131ACG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of the Free State</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9300</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KIDCRU</name>
      <address>
        <city>Cape Town</city>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. J. Fourie Medical Practice</name>
      <address>
        <city>Dundee</city>
        <zip>3000</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Empilweni Services and Research Unit (ESRU)</name>
      <address>
        <city>Johannesburg</city>
        <zip>2093</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Be Part Yoluntu Centre</name>
      <address>
        <city>Paarl</city>
        <zip>7626</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vx Pharma</name>
      <address>
        <city>Pretoria</city>
        <zip>87</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perinatal HIV Research Unit</name>
      <address>
        <city>Soweto</city>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HIV-NAT</name>
      <address>
        <city>Bangkok</city>
        <state>Krung Thep Maha Nakhon</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <state>Krung Thep Maha Nakhon</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>South Africa</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 16, 2013</study_first_submitted>
  <study_first_submitted_qc>December 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2013</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatrics</keyword>
  <keyword>Adolescents</keyword>
  <keyword>HIV</keyword>
  <keyword>HIV-1</keyword>
  <keyword>Treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cobicistat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

